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Abbreviations
ACEi, angiotensin converting enzyme inhibitor
AKI, acute kidney failure
ARB, angiotensin receptor blocker
ARDS, acute respiratory distress syndrome




COVID-19, 2019 novel coronavirus disease
DM, diabetes mellitus
FiO2, fraction of inspired oxygen
HR, hazard ratio
ICU, intensive care unit
IL, interleukin
imTOR, mammalian target of rapamycin inhibitor
IQR, interquartile range
KT, kidney transplant
LDH, lactic acid dehydrogenase
MMF, mycophenolate mofetil
PaFi, PaO2/FiO2
PaO2, partial pressure of oxygen
ROC, receiver operating characteristic curve
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SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
SD, standard deviation
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Abstract
Acute respiratory distress syndrome associated with coronavirus infection is related to a cytokine storm 
with large interleukin 6 (IL-6) release. The IL-6-receptor blocker tocilizumab may control the aberrant host 
immune response in COVID-19 patients. In this pandemic, kidney transplant (KT) recipients are a high-risk 
population for severe infection and showed poor outcomes. We present a multicenter cohort study of 80 KT 
patients with severe COVID-19 treated with tocilizumab during hospital admission. High mortality rate 
was identified (32.5%), related with older age (HR 3.12 for those older than 60 years, p=0.039). IL-6 and 
other inflammatory markers, including LDH, ferritin, and D-dimer increased early after tocilizumab 
administration and their values were higher in non-survivors. Instead, C-reactive protein (CRP) levels 
decreased after tocilizumab, and this decrease positively correlated with survival (mean 12.3 mg/L in 
survivors vs. 33 mg/L in non-survivors). Each mg/L of CRP soon after tocilizumab increased the risk of 
death by 1% (HR 1.01 [CI 1.004-1.024], p=0.003). Although patients who died presented with worse 
respiratory situation at admission, this was not significantly different at tocilizumab administration, and did 
not impact on outcome in the multivariate analysis. Tocilizumab may be effective in controlling cytokine 
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1. Introduction
World Health Organization declared severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-
CoV-2) outbreak as a pandemic on March 11th, 20201. During the last nine weeks, Spain has been one of 
the most affected countries worldwide, with more than 235.000 people infected by May 26th and almost 
27.000 deaths (fatality rate of 11.4%)2. At the same time, in Spain we have the privilege of enjoying one of 
the highest kidney transplantation (KT) rates across the world, with 72.8 procedures p.m.p performed in 
2019 and more than 33.000 prevalent KT recipients with a functioning kidney3. This specific population is 
considered to be at risk for COVID-19 disease due to several conditions as their intrinsic comorbidities, the 
immunosuppressed status, and their frequent contact with health facilities4–6. In fact, more than 500 KT 
recipients have been reported to have COVID-19 through the Spanish Society of Nephrology registry7,8, 
resulting in a global incidence of 1.5%, which triplicates general population. 
The clinical presentation of COVID-19 includes fever, cough, dyspnea, gastro-intestinal symptoms and, 
eventually, respiratory failure9.  So far, no treatment has solidly proven to be effective in stopping or 
ameliorating COVID-19 evolution10,11. Tocilizumab is a humanized antibody against the receptor of 
interleukin-6 (IL-6) that has been mostly used in rheumatoid arthritis, although its indications include other 
rheumatic conditions and severe cytokine release syndrome induced by CAR-T cells12. In the setting of 
transplantation, tocilizumab has been used to treat chronic antibody-mediated rejection13. Considering that 
the acute respiratory distress syndrome (ARDS) that occurs in some patients throughout COVID-19 is a 
consequence of an inflammatory response, tocilizumab appears as a reasonable drug to target the 
presumable cytokine storm triggered by the virus. Preliminary data in the general population14–17 and 
transplant patients18–20 show promising results. 
Herein we present the results of tocilizumab use in a multicenter cohort of 80 Spanish KT recipients 
affected with SARS-CoV-2. 
2. Methods
2.1. Patients
KT patients were identified from the Spanish Society of Nephrology COVID-19 registry, which included 
dialysis and KT patients with confirmed diagnosis of COVID-19 since 18th March 20207. Only patients 
with a reverse-transcriptase–polymerase-chain-reaction (RT-PCR) positive assay of a specimen collected 
on a nasopharyngeal swab or bronchoalveolar lavage were included. Initially, from 468 KT recipients 
included in the registry until the 9th of May, 73 were identified to have been treated with tocilizumab in 29 
different hospitals in Spain. In a second step, a complete database was created in order to gather granular 
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completing the additional variables. Twenty-seven centers completed the database and seven more patients 
were added, resulting in a final number of 80 patients. Median time to follow-up since symptoms onset was 
25 days, interquartile range (IQR) 17-35 days.
2.2. Variables collected and definitions
The registry already included demographics, baseline kidney disease information, immunosuppressive and 
renin-angiotensin-system inhibitors treatments, and epidemiological and clinical data regarding COVID-19: 
date of diagnosis, symptoms, lymphopenia, pharmacological treatments, need of mechanical ventilation or 
intensive care and outcome. More specific and detailed data regarding tocilizumab treatment and 
inflammatory markers were added in the expanded database.
Obesity was defined as a body mass index (BMI) over 30 Kg/m2. Respiratory symptoms included cough, 
sneezing and rhinorrhea but excluded dyspnea, which was collected separately. The ratio of arterial oxygen 
partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction) or PaFi index 
(Pa/FiO2) was calculated when available (n=38). If data to calculate it were missing, oxygen saturation was 
included (n=40). 
Criteria for tocilizumab treatment was based on the protocol of each hospital although all patients presented 
with one of the following: increased levels or IL-6 (usually >40, ranged between >20 to >60 pg/mL), 
increased levels of other inflammatory markers (such as C-reactive protein (CRP), D-dimer, ferritin or 
lactic acid dehydrogenase (LDH)), and/or rapidly progressive ARDS (usually with PaFi<300). 
Generally, tocilizumab dose was 8 mg/kg, adjusting to 600 mg for patients >75 or 80 kg body weight and 
400 mg for those <75-80 kg. Depending on the clinical and analytical response, patients could receive two 
doses of tocilizumab, separated by 12 hours in the majority of the cases.
Clinical follow-up and lab tests were collected at three points: at admission, at the time tocilizumab was 
administered and early after tocilizumab infusion (median 72 h, IQR 48-96 h).
Outcomes were assessed as COVID-19-related mortality or recovery until May 15th, 2020. Recovery was 
defined as hospital discharge. 
The study was performed under the principles of the Declaration of Helsinki and was approved by the 
hospital ethics committee.
2.3. Statistical analysis
Quantitative variables with a normal distribution are expressed as mean and standard deviation (SD) and 
the remaining as median and IQR. Categorical variables are summarized as counts and percentages. 
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variables and non-parametric test for non-normal distributed ones. Cox multivariate analysis was assessed 
for predictors of patient mortality. Results are expressed as hazard ratio (HR) with their 95% confidence 
intervals (95% CIs). In the multivariate analysis only those variables with a p value <0.05 and clinically 
relevant for the outcome were included. A receiver operating characteristic (ROC) curve was plotted to 
illustrate the diagnostic ability of a binary classifier system as its discrimination threshold is varied. In 
general, a p value <0.05 was considered statistically significant. Statistical analysis was performed using 
SPSS V 22.0 (SPSS Inc., Chicago, IL).
3. Results
Fatality rate in this cohort was 32.5%. Table 1 summarizes baseline characteristics of the entire cohort 
(n=80), patients who survived (n=54), and those who died (n=26). Mean age was 59.3 years and patients 
who died were five years older and more obese, with almost one third of them presenting with a BMI over 
30 Kg/m2. There were no other differences regarding recipient comorbidities. Most of them were on 
calcineurin inhibitors and mycophenolate. Clinical presentation most frequently included fever (81.3%) 
accompanied by other respiratory symptoms (cough, rhinorrhea) in 77.5% of them. Dyspnea and 
deteriorated respiratory situation (PaFi<300 or oxygen saturation<96%) were more frequent at the time of 
admission in those who died later on. Blood tests at admission showed a low lymphocyte count and 
elevated inflammatory markers, without relevant differences between those patients who died and those 
who survived, except for D-dimer, which was higher in patients who ultimately died.
COVID-19 management is summarized in table 2. All patients received tocilizumab at a median time of 5 
days after admission. This elapsed time was longer in those who died in comparison with survivors (6 vs 4 
days), though the difference was not statistically significant (p=0.13). Tocilizumab was more frequently 
administered at ICU in those who died, as median time from admission to administration was 6 days, and 
median time from admission to ICU was 5 days. Sixteen patients received more than one dose of 
tocilizumab. These patients were not more severely affected at baseline, but respiratory deterioration was 
more profound, with more frequent ICU admission and a higher mortality (supplementary table 1). Six 
patients treated with tocilizumab and steroids showed superimposed bacterial pneumonia.
Most patients received hydroxychloroquine (98.8%) and antibiotics (76.3%) while antivirals were less 
frequently used (48.8%). The use of steroid pulses together with tocilizumab was the most common 
practice (80%), and they were more often prescribed in those who died than in survivors (96.2% vs 72.2). 
Similarly, interferon was only administered in 5 patients and all of them died. Most patients withdrew 
immunosuppressive medications, either only antimetabolites (33.8%) or both antimetabolites and 
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Outcomes are also detailed in table 2. Those who died were more often admitted to the ICU and had more 
frequent and severe acute kidney failure as COVID-19 complication.
The percentage of patients with severe respiratory disease (PaFi index <300 mmHg or Oxygen saturation 
<96%) at admission was higher in patients who ultimately died than in survivors (68% vs 41.5%, p<0.01). 
At the moment of tocilizumab treatment these percentages were not different between survivors and non-
survivors (81.6% vs 87.5%) (Figure 1). 
Predictors for mortality were analyzed through multivariable Cox analysis (table 3). Recipient age over 60 
and C-reactive protein (CRP) serum level after tocilizumab were associated with an increased risk of death. 
Each mg/L of CRP soon after tocilizumab administration increased the risk of death by 1% (p=0.003). A 
worse baseline respiratory situation and obesity were not significantly related to mortality in the 
multivariate adjustment. ARDS did not help on differentiating between survivors and non-survivors on 
final outcome.
We also analyzed laboratory parameters at different points during hospital stay (figure 2). At the time of 
tocilizumab administration all measurements had worsen compared to the status at admission, both in 
survivors and in those who had died at the end of follow-up. Early after tocilizumab administration only 
CRP levels decreased while other inflammatory markers increased even more. CRP levels markedly 
decreased after tocilizumab in survivors. In an attempt to identify which patients would have a favorable 
response to tocilizumab, we plotted a ROC curve for CRP levels soon after tocilizumab infusion, finding 
that values over 30 mg/L had a moderate estimation (0.648; p=0.042) for patient death. 
The 80 patients treated with tocilizumab were compared with 335 ones not treated with tocilizumab but 
with COVID-19 symptoms and hospital admission. Age, gender, primary kidney disease, baseline 
immunosuppressive treatment and KT vintage were similar between both groups. Those patients treated 
with tocilizumab were more severely ill than those left untreated, as they had more frequently pneumonia, 
other concomitant drug treatments, ICU admission, non-invasive mechanical ventilation or endotracheal 
intubation, and a higher mortality (supplementary table 2).  
4. Discussion
We present the results of the largest cohort of KT recipients with COVID-19 treated with tocilizumab. In 
our report, 80 patients have been analyzed and the fatality rate was 32.5%. Inflammatory markers increased 
early after tocilizumab administration, however CRP decreased, significantly more in survivors. There were 
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Several reports including low number of patients have reported outcomes of KT recipients with COVID-
196,8,20–22. In these studies, mortality ranged amongst 6 to 28%. The Spanish Society of Nephrology registry 
reported a mortality of 23.6% in 535 KT recipients with confirmed COVID-197. Our study cohort has a 
high mortality, but given the severity of respiratory disease at baseline, it is likely that mortality may have 
been lower than expected. Our patient cohort presented with ARDS in 80% of cases and they required 
hospitalization and several pharmacological treatments, including tocilizumab. 
Tocilizumab is a potent anti-inflammatory drug indicated for chronic conditions and mainly used in 
rheumatoid arthritis12. In the pathogenesis of severe COVID-19, a cytokine storm occurs, involving release 
of proinflammatory cytokines including IL-6, tumor necrosis factor-α (TNF-α), and others23–25. High 
plasma levels of cytokines have been found in COVID-19 patients admitted to the ICU, evidencing that the 
cytokine storm is related with the severity of the disease9,26. As dysregulated IL-6 synthesis is thought to 
play a key role in this cytokine storm, similar to what happens in autoimmune diseases and malignancy, 
targeting IL-6 is a potential therapeutic approach for severe and critical COVID-19. The largest series 
reported so far in the general COVID-19 population included 100 patients from Brescia, Italy17. After two 
doses of tocilizumab, 77% of patients improved respiratory distress. In another Chinese experience in 21 
patients, the authors reported significant clinical improvement in all patients, including two who were 
critically ill, within five days after tocilizumab administration16. 
Previous published experience with tocilizumab treatment in transplant recipients is limited to the good 
outcomes in a liver transplant recipient18 and a KT one19, and a short series of 14 cases included in a report 
from New York20. In the latter, Pereira et al used tocilizumab in patients who deteriorated rapidly, with five 
of them receiving the initial dose after intubation. Of these 14 patients, three died and four remained in the 
ICU at last follow-up, so it is likely that the final mortality was around 40%, quite similar to ours. In our 
series, tocilizumab was used in around 20% of all Spanish COVID-19 registered KT recipients7 and it is 
likely that this subset comprised the most severely affected patients. 
Patients who finally died were more severely ill at the admission, but with similar severity at the time of 
tocilizumab administration. In addition, we did not find differences regards respiratory improvement 72h 
after tocilizumab administration between survivors and non-survivors, and, therefore, this might not be an 
early predictor of good outcome. Previous experiences have reported early response to tocilizumab 
administration regarding respiratory parameters16,17, although in the largest series of patients this 
improvement seems to be more important 10 days after tocilizumab administration17. 
In terms of other drugs, patients who died received more frequently steroids and interferon. It is likely that 
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administration and 10% of patients presented with bacterial microbiological finding after tocilizumab 
infusion.
We observed that most inflammatory markers increased after tocilizumab in the whole cohort, although we 
could speculate that we had prevented an even higher increase. IL6 levels have been described to increase 
and then decrease in most patients after starting tocilizumab therapy15,17.  The explanation is that binding of 
tocilizumab to IL-6 receptor inhibits receptor-mediated clearance of IL-6, leading to its accumulation in 
serum. A later decrease of IL-6 by interfering the stimulus for the exaggerated immune response might 
result in stabilization or improvement of clinical outcome. Additionally, not only IL-6 but also D-dimer 
may increase up to ten days after tocilizumab treatment17. In our study, CRP was the only marker that 
decreased within 72 hours after tocilizumab administration and differentiated those who finally resolved the 
infection from those who died. This is not an isolate finding from our data. CRP has been reported to 
decrease rapidly in patients treated with TCZ for COVID-1915,17–19 and might help to predict outcomes soon 
after the treatment.
Our study has limitations. The retrospective nature of the study made it impossible to get the whole set of 
variables in all patients. Furthermore, we do not have a control group. Criteria for administration was 
disease severity and patients who received the drug were in worse conditions than an eventual control 
group not receiving the drug. A propensity cohort was not available for comparison, as very few KT 
patients with COVID-19 were left untreated when tocilizumab was indicated by center protocols. In fact, 
when we compared our 80 patients treated with tocilizumab with the 335 admitted ones not treated with 
tocilizumab, those treated with tocilizumab were more severely ill (more pneumonia, ICU admission and 
mechanical ventilation) than those left untreated. As a result, direct comparison between treated and 
untreated subgroups is not useful. Contrarily, the comparison between those who received tocilizumab and 
died and those who received the drug and survived was very informative. The disease presentation was 
different between them, and non-survivors were more severely ill since the beginning and received 
tocilizumab more frequently at the ICU. However, survivors and non-survivors presented equally affected 
at the time of tocilizumab administration and we could analyze the early response to treatment. Apart from 
the clinical response, we observed how inflammatory markers increased on both groups except for CRP -
whose production is stimulated by IL6-, which decreased more significantly in the group of survivors. 
In summary, we present a large cohort of KT patients treated with tocilizumab for COVID-19 management. 
Mortality in this group was high but it may have been lower than expected given the severity of respiratory 
disease. CRP levels early after tocilizumab administration together with clinical and radiological response 
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immunosuppressed patients with COVID-19 who develop ARDS needs to be further assessed in larger 
randomized controlled trials.
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Figure legends
Figure 1. Percentage of patients with severe respiratory situation – defined as PaFi<300 or oxygen 
saturation <96%- at different points between patients who died and those who survived. Differences were 
found (p=0.02) only at the time of admission.
PaFi, arterial oxygen partial pressure/fraction of inspired oxygen
**p<0.01
Figure 2. Laboratory findings regarding COVID-19 infection evolution and tocilizumab (TCZ) use. 
Differences between alive and dead patients at three time points; admission, TCZ administration and 72 h 
after TCZ. A) Ferritin levels significantly increased in survivors along the inpatient stay. B) Lactic acid 
dehydrogenase (LDH) levels increased after TCZ in patients who died and were significantly higher than in 
survivors at TCZ and after TCZ. C) Procalcitonin decreased in survivors and levels after TCZ were higher 
in patients who died. D) Interleukin-6 (IL-6), remained increased during admission, and the increase was 
especially relevant after TCZ treatment in patients who finally died. E) D-dimer was significantly higher in 
those patients who died at TCZ and after TCZ, but levels increased along time in both subgroups. F) C-
reactive protein (CRP) initially increased and levels were similar between groups at TCZ treatment, 
however, although levels decreased after TCZ in all patients, survivors experienced a higher decrease. 
Continue lines represent comparisons at different time points in recipients who survived. Discontinue lines 
represent comparisons at different time points in those who died. Black asterisks regard to comparison 
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Table 1. Baseline characteristics of all KT patients with COVID-19 infection who received tocilizumab as 










Recipient age (years, mean ± SD) 59.3 ± 11.7 57.6 ± 11.6 62.9 ± 11.2 0.05
Recipient age 60 years (n, %) 42 (52.2) 23 (42.6) 19 (73.1) 0.01
Female gender (n, %) 26 (32.5) 23 (33.3) 8 (30.8) 0.81
Caucasian race (n, %) 71 (88.8) 46 (85.2) 25 (96.2) 0.33
Underlying kidney disease
     Diabetic nephropathy (n, %) 15 (18.8) 11 (20.4) 4 (15.4)
     Vascular (n, %) 7 (8.8) 5 (9.3) 2 (7.7)
     Glomerular disease (n, %) 17 (21.3) 12 (22.2) 5 (19.2)
     PKD (n, %) 14 (17.5) 7 (13) 7 (26.9)
     Other (n %) 27 (33.8) 19 (35.2) 8 (30.8)
0.66
Retransplantation (n, %) 21 (26,2) 17 (31.5) 4 (15.4) 0.12
Smoking status (current or past) (n, %) 17 (21.3) 10 (18.5) 7 (26.9) 0.33
Comorbidities
Lung disease (n, %) 7 (8.8) 4 (7.4) 3 (11.5) 0.54
Ischemic heart disease (n, %) 13 (16.3) 7 (13) 6 (23.1) 0.25
Hypertension (n, %) 71 (88.8) 50 (92.6) 21 (80.8) 0.11
Diabetes mellitus (n, %) 23 (28.7) 38 (70.4) 19 (73.1) 0.80
History of cancer (n, %) 17 (21.5) 9 (17) 8 (30.8) 0.16
Obesity – BMI > 30kg/m2 (n, %) 14 (17.5) 6 (11.1) 8 (30.8) 0.03
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Immunosuppression
Thymoglobulin induction (n, %) 33 (41.3) 24 (44.4) 9 (34.6) 0.34
Calcineurin inhibitor (n, %) 66 (82.5) 46 (85.2) 20 (76.9) 0.36
Prednisone (n, %) 73 (91.3) 50 (92.6) 23 (88.5) 0.54
Mycophenolate (n, %) 64 (80) 44 (81.5) 20 (76.9) 0.63
mTOR inhibitor (n, %) 14 (17.5) 10 (18.5) 4 (15.4) 0.73
At admission
Time after transplant (months, median [IQR]) 72 (16.5-165) 60 (18-143) 90 (16-186) 0.59
Time between onset of symptoms to admission 
(days, median [IQR])
-4 (-8 to -3) -4 (-8 to -3) -4.5 (-7 to -2.5) 0.72
Symptoms
    Fever (n, %) 65 (81.3) 43 (79.6) 22 (84.6) 0.59
    Dyspnea (n, %) 46 (57.5) 27 (50) 19 (73.1) 0.05
    Respiratory symptoms (n, %) 62 (77.5) 42 (77.8) 20 (76.9) 0.93
    Gastrointestinal symptoms (n, %) 38 (48.1) 30 (56.6) 8 (30.8) 0.03
Respiratory situation
     PaO2/FiO2 (mmHg, median [IQR]) (n=38) 319 (256-434) 324 (274-452) 281 (160-420) 0.26
     ARDS moderate-severe (PaFi<200) (n, %) 6 (2.6) 2 (7.4) 4 (36.4) 0.04
     ARDS (PaFi<300) (n, %) 17 (44.7) 10 (37) 7 (63.6) 0.13
    Oxygen saturation (%, median [IQR]) 
(n=40)
95 (91-97) 96 (93-97) 91 (90-96) 0.007
    Oxygen saturation<96% (n, %) (n=40) 22 (55) 12 (46.2) 10 (71.4) 0.12
    PaFi<300 or Oxygen saturation<96% (n, %) 
(n=78)
39 (50) 22 (41.5) 17 (68) 0.02
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    White blood cells (x10*3/uL, mean ± SD) 6.8 (3.1) 6.8 (3.2) 6.7 (2.9) 0.55
    Neutrophils (x10*3/uL, mean ± SD) 5.6 (3) 5.6 (3.1) 5.6 (2.8) 0.63
    Lymphocytes (x10*3/uL, mean ± SD) 0.78 (0.6) 0.8 (0.9) 0.7 (0.4) 0.78
    CRP (mg/L, median [IQR]) 48.5 (10.1-48.5) 34.1 (9.1-114) 80 (20.8-174.2) 0.09
    Procalcitonin (ng/mL, median [IQR]) 0.24 (0.1-1.1) 0.19 (0.13-0.8) 0.53 (0.10-1.7) 0.37
    IL-6 (pg/mL, median [IQR]) 52 (33-110) 50 (28-90) 103 (45-128) 0.13
    Log IL-6 (pg/mL, mean ± SD) 4.1 (1.1) 3.9 (0.9) 4.6 (1.2) 0.11
    LDH (UI/L, median [IQR]) 335 (257-485) 330 (256-479) 366 (257-526) 0.59
    Ferritin (ng/mL, median [IQR]) 698 (393-1677) 686 (358-1626) 1335 (581-2286) 0.15
    D-dimer (mcg/L, median [IQR]) 900 (475-1730) 605 (410-1196) 1684 (1109-2322) 0.001
SD, standard deviation; PKD, polycystic kidney disease; DM, diabetes mellitus; BMI, body mass index; ACEi, angiotensin 
converting enzyme inhibitor; ARB, angiotensin receptor blocker; IQR, interquartile range; PaO2, partial pressure of oxygen; 
FiO2, fraction of inspired oxygen; PaFi, PaO2/FiO2; ARDS, acute respiratory distress syndrome; mTOR, mammalian target 










This article is protected by copyright. All rights reserved
Table 2. Management and outcomes of KT with COVID-19 infection who received tocilizumab as part of 










Time since admission to tocilizumab treatment 
(days, median [IQR])
5 (2-8) 4 (2-7) 6 (3-10) 0.13
Time since onset of symptoms to tocilizumab 
treatment (days, median [IQR])
10 (7-15) 10 (8-15) 12 (6-15.7) 0.55
Tocilizumab >1 dose (%) 16 (20) 7 (13) 9 (34.6) 0.02
Hydroxychloroquine (n, %) 79 (98.8) 54 (100) 25 (96.2) 0.14
Azithromycin (n, %) 59 (73.8) 41 (75.9) 18 (69.2) 0.52
Other antibiotic (n, %) 61 (76.3) 41 (75.9) 20 (76.9) 0.92
Steroids (n, %) 64 (80) 39 (72.2) 25 (96.2) 0.01
     Time since admission to steroids treatment    
     (days, median [IQR])
3 (1-7) 3 (1-7) 2 (1-5) 0.85
Ritonavir/lopinavir/remdesvir (n, %) 39 (48.8) 23 (42.6) 15 (57.7) 0.12
Interferon (n, %) 5 (6.3) 0 5 (19.2) 0.001
IV immunoglobulins (n, %) 12 (15) 7 (12.9) 5 (19.2) 0.33
Anakinra (n, %) 6 (7.5) 2 (3.7) 4 (15.4) 0.08
Immunosuppression management
Only CNI withdrawal (n, %) 4 (5.2) 3 (5.8) 1 (4) 0.73
Only MMF or imTOR withdrawal (n, %) 26 (33.8) 15 (28.8) 11 (44) 0.18
Both CNI and MMF or imTOR withdrawal (n, %) 43 (55.8) 31 (59.6) 12 (48) 0.33
Outcomes and follow-up
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Time since hospital admission to ICU admission 
(days, median [IQR])
7 (3.7-12) 9 (4.5-16.5) 5 (2.5-11) 0.92
Non-invasive mechanical ventilation (n, %) 33 (44) 17 (33.3) 16 (66.7) 0.012
Endotracheal intubation (n, %) 19 (25) 5 (9.8) 14 (56) <0.001
Acute kidney injury (n, %) 36 (45) 20 (37) 16 (61.5) 0.04
    with dialysis need (n, %) 15 (18.8) 6 (11.1) 9 (34.6) 0.01
Acute rejection (n, %) 1 (1.3) 0 1 (3.8) 0.14
Chest X-ray improvement after tocilizumab 32 30 (56.6) 2 (7.7) <0.001
IQR, interquartile range; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; imTOR, mammalian target of rapamycin 
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Table 3. Cox multivariate analysis showing predictors of patient death.
HR CI 95% p-value
Age >60 years 3.12 1.05-9.26 0.039
CRP after tocilizumab 1.01 1.004-1.024 0.003
PaFi<300 or Oxygen saturation<96% 1.73 0.62-4.84 0.294
Obesity 1.65 0.66-4.10 0.278
HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; PaO2, partial pressure of oxygen; FiO2, fraction of 
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Figure 1. Percentage of patients with severe respiratory situation – defined as PaFi<300 or oxygen 
saturation <96%- at different points between patients who died and those who survived. Differences were 
found (p=0.02) only at the time of admission.
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Figure 2. Laboratory findings regarding COVID-19 infection evolution and tocilizumab (TCZ) use. 
Differences between alive and dead patients at three time points; admission, TCZ administration and 72 h 
after TCZ. A) Ferritin levels significantly increased in survivors along the inpatient stay. B) Lactic acid 
dehydrogenase (LDH) levels increased after TCZ in patients who died and were significantly higher than in 
survivors at TCZ and after TCZ. C) Procalcitonin decreased in survivors and levels after TCZ were higher 
in patients who died. D) Interleukin-6 (IL-6), remained increased during admission, and the increase was 
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those patients who died at TCZ and after TCZ, but levels increased along time in both subgroups. F) C-
reactive protein (CRP) initially increased and levels were similar between groups at TCZ treatment, 
however, although levels decreased after TCZ in all patients, survivors experienced a higher decrease. 
Continue lines represent comparisons at different time points in recipients who survived. Discontinue lines 
represent comparisons at different time points in those who died. Black asterisks regard to comparison 
between different time-points and grey asterisks between dead and alive patients. *p<0.05; **p<0.01; 
***p<0.001 
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